CN104473960A - Pharmaceutical composition used for treating neuropathic pain - Google Patents
Pharmaceutical composition used for treating neuropathic pain Download PDFInfo
- Publication number
- CN104473960A CN104473960A CN201410628700.5A CN201410628700A CN104473960A CN 104473960 A CN104473960 A CN 104473960A CN 201410628700 A CN201410628700 A CN 201410628700A CN 104473960 A CN104473960 A CN 104473960A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- neuropathic pain
- treatment
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition used for treating neuropathic pain. The pharmaceutical composition is prepared by taking morin, senegenin A, syringopicroside, and clerodendrin A as drug substances via mixing. Different dosage forms can be obtained via conventional pharmaceutical technology. Defects of the prior art are avoided; the pharmaceutical composition possesses substantial curative effects on neuropathic pain, and is safe. A preparation method of the pharmaceutical composition is simple; cost is low; it is confirmed by clinical experiments that the pharmaceutical composition possesses substantial clinical curative effects on neuropathic pain including prosopalgia, sciatica, radicular neuralgia, post-herpetic neuralgia, and diabetes nerve ending inflammation.
Description
Technical field
The invention belongs to the field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of neuropathic pain.
Background technology
Neuropathic pain refers to the pain syndrome caused by central or peripheral nervous system novo lesions or dysfunction.Can by wound or/and disease cause peripheral nerve, spinal cord after root, spinal cord and some site tissue damage of above nervus centralis thereof and cause.According to the cause of disease, the nature and extent difference of nerve injury, be divided into the large class of the peripheral nerve pain two caused by nervus centralis pain and peripheral nerve injury clinically.Nervus centralis pain is called for short central pain, and infringement or dysfunction and the idiopathic pain that causes occur the pain transduction path for central nervous system, are common in wound or the cerebrovascular disease of spinal cord, multiple sclerosis and tumor etc.Caused by the factor such as peripheral nerve pain system wound, ischemia, compressing, infection, inflammation, metabolism damage peripheral nervous, as phantom pain, postherpetic neuralgia, polyneuritis, Diabetic Peripheral neuralgia etc.According to estimates, this disease is just tormenting the population of global 2.8%-4.7%, and the incidence rate of epidemiology display general population is 6%-7.7%.After diabetes nerve pain and herpes zoster, secondary pain is the bitterly the most general form of adult neural, and incidence rate is respectively 13%-37% and 10%-40%, and along with the aging incidence rate of population is higher, annual morbidity is 12/,100,000.The sickness rate of neuropathic pain syndrome in old people improves constantly: be on the one hand cancer, HIV, diabetes and other patient often causing the Disease long-term survival of neuropathic pain increase; On the other hand, also neuropathic pain can be produced when medicine and surgical operation therapy tumor and Other diseases.During morbidity patient usually have pain as calcination, tingle or just like electric shock pain, very acutely, as cutter cut out as severe pain.This pain is suddenly shown effect, and the position of pain and scope thereof, be limited to the domination field of this nerve.During outbreak, the neural position near epidermis of pressure, will feel violent pain.Neuropathic pain can produce great impact to the life of patient, the work that it has seized a lot of people, the ability of even wearing the clothes on foot.
Do not have a kind of medicine safely and effectively can alleviate the misery of this kind of patient in the market.Treat multiplex anticonvulsant, opioid drug and anti depressant medication, but most product is not specially for neuropathic pain, great majority are invalid or can only appropriate alleviating pain to most of patient, and can cause untoward reaction.Therefore, improve treatment and the prevention level of neuropathic pain, improve neuropathic pain quality of life of patients, the medicine of exploitation control neuropathic pain is significant.
Morin (morin): CAS 480-16-0, molecular formula C
15h
10o
7, chemical name: 3,5,7,2 ', 4 '-pentahydroxyflavone, (3,5,7,2 ', 4 '-Tricetin).Antibacterial, anticancer, inhibitory enzyme activity, there is antioxidation, anti-pain, antibacterial, antiinflammatory, atherosclerosis, the effect such as reduction blood glucose and anti-stress.
Polygalic acid A(onjisaponin A): CAS 82410-33-1, molecular formula C
80h
120o
39, molecular weight 1705.79.
Syringopicroside (syringopicroside): CAS 29118-80-7, molecular formula C
24h
30o
11, molecular weight 494.4884.There is antivirus action.
Clerodendrin A(clerodendrin A): CAS 35481-70-0, molecular formula C
31h
42o
12, molecular weight 606.67.
Form constituent structure in 4 of pharmaceutical composition of the present invention as follows:
Morin (morin)
Polygalic acid A(onjisaponin A)
Syringopicroside (syringopicroside)
Clerodendrin A(clerodendrin A).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, a kind of pharmaceutical composition for the treatment of neuropathic pain of evident in efficacy, safe without toxic side effect is provided.
The present invention adopts following technical scheme to realize: composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment neuropathic pain are:
Morin 20-30 weight portion polygalic acid A15-25 weight portion syringopicroside 10-20 weight portion clerodendrin A5-15 weight portion.
A kind of pharmaceutical composition for the treatment of neuropathic pain of the present invention can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
A kind of pharmaceutical composition for the treatment of neuropathic pain of the present invention, is characterized in that being used for the treatment of trigeminal neuralgia, sciatica, radicular pain, postherpetic neuralgia, diabetic nerve tip inflammation.
The present composition has effect of wind-expelling pain-stopping, promoting blood circulation to remove obstruction in the collateral, to the various neuropathic pain for the treatment of, as evident in efficacy in diseases such as root neuropathic pain, sciatica, trigeminal neuralgia, postherpetic neuralgia, diabetic peripheral neuritiss.
Detailed description of the invention
Embodiment 1: the pharmaceutical composition for the treatment of neuropathic pain
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of neuropathic pain are:
Morin 20 weight portion polygalic acid A25 weight portion syringopicroside 10 weight portion clerodendrin A15 weight portion.
Embodiment 2: the pharmaceutical composition for the treatment of neuropathic pain
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of neuropathic pain are:
Morin 30 weight portion polygalic acid A15 weight portion syringopicroside 20 weight portion clerodendrin A5 weight portion.
Embodiment 3: the pharmaceutical composition for the treatment of neuropathic pain
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of neuropathic pain are:
Morin 25 weight portion polygalic acid A20 weight portion syringopicroside 17 weight portion clerodendrin A10 weight portion.
Embodiment 4: the pharmaceutical composition for the treatment of neuropathic pain
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of neuropathic pain are:
Morin 28 weight portion polygalic acid A22 weight portion syringopicroside 16 weight portion clerodendrin A8 weight portion.
Embodiment 5: the preparation of tablet
Example 1 compositions 150g, adds starch 75g, mixing, granulates, dry, adds microcrystalline Cellulose 20g, magnesium stearate 2.5g, and mixing, is pressed into 1000, obtains present composition tablet.
Embodiment 6: the preparation of capsule
Example 2 compositions 165g, adds starch 65g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains present composition capsule by encapsulated 1000.
Embodiment 7: the preparation of drop pill
Taking polyethylene glycol 6000 200g water-bath (80 DEG C) heating boils molten, add embodiment 3 compositions 50g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 10 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2cm apart from liquid level, drips speed with per minute 50 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain present composition drop pill.
Experimental example 1, glutamic acid caused to PC12 cell injury affect experimental study
1. test material
1.1 medicines and reagent
Sample: embodiment 1-4 compositions
Cell line: PC12 cell line ((source: Ratt μ s norvegic μ s Adrenal Pheochromocytoma, Nanjing KaiJi Biology Science Development Co., Ltd provides.）；
Reagent: H-DMEM cell culture medium (Hyclone, Sai Mo fly generation that biochemistry goods Beijing company limited); Hyclone (Israel Bioind); Pancreatin cell dissociation buffer (the green skies), penicillin streptomycin mixed liquor is dual anti-, cisplatin for inj (Qilu Pharmaceutical Co., Ltd.), citrate buffer (Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge), paraformaldehyde (solarbio), Pidolidone (Klonetech, Japan).
1.2 test apparatus
Vertical pressure steam sterilization pan (LDZX-50FBS, Shen, Shanghai is pacified); Double one side clean work station (SW-CJ-1C, Suzhou purifies); CO2 gas incubator (BB16 μ V/BB5060 μ V, HERAE μ S); Desk centrifuge (H3, Sigma); Microplate reader (M μ ltiskan MK3, Thermo Scientific); Electric heating constant-temperature blowing drying box (101, Shanghai roc is along scientific instrument company limited); Inverted microscope (XDS-1B, Chongqing optical instrument factory); Water-bath constant temperature oscillator (SHZ-82, Medical Instruments factory of Jintan City); Pipettor (Gilson, Eppendorf); Culture bottle (Corning); 96 orifice plates (Costar, μ SA)
2. test method
Prepare PC12 cytochemistry damage model with glutamic acid, adopt tetrazolium bromide (MTT) method to measure absorption value in 570nm place, observe drug candidate to the repair of PC12 cell injury.Use SOD, NO, LDH, MDA test kit to detect each index content, illustrate the mechanism of action of each medicine.
The glutamic acid (this is application of sample final concentration, is dissolved in incomplete culture medium) of modeling: 30mmol/l acts on PC12 cell 24h.
Grouping: blank group, chemical damage model group, chemical damage+medicine group.
3. content of the test
3.1 cell culture
Frozen PC12 cell recovery is got in culture bottle, with the H-DMEM culture medium culturing containing 10% hyclone from ultra cold storage freezer.When PC12 Growth of Cells to 80% merges, digest, be inoculated in 96 orifice plates with 1 × 104 cell per well with the pancreatin cell dissociation buffer (containing 0.02%EDTA) of 0.25%, zeroing hole does not add cell.
3.2 cell injury
After the cell in 96 orifice plates covers with monolayer, discard culture medium, aseptic PBS liquid cleans 2 times, except zeroing group, blank group, every hole adds the glutamic acid (being dissolved in incomplete culture medium) that final concentration is 30mmol/l and cultivate 24h in incubator, namely causes PC12 cell injury model.
3.3 dosing reparations
Discard culture medium, clean 2 times with aseptic PBS liquid, the every hole of administration group adds the DMEM culture medium 100 μ l being followed successively by 100 μ g/ml, 10 μ g/ml, 1 μ g/ml containing screening of medicaments final concentration respectively, and the medicine of each concentration adds 6 holes.With the DMEM culture medium of not drug containing for blank group.Then cell inserted 37 DEG C, continue in 5%CO2 incubator to cultivate 24h.
3.4 index determining
3.4.1 mtt assay measures cell survival rate
After discarding culture medium, every hole adds 100 μ l plasma-free DMEM medium, then adds 5mg/mlMTT solution 20 μ l lucifuge in incubator in every hole and react 4 h.Discard culture medium and add 100 μ lDMSO microplate reader in 570nm mensuration OD value, calculate cell survival rate:
3.4.2 SOD, LDH assay
Within after administration 24 hours, centrifugal 20 minutes (2000r/min), carefully collects supernatant, by test kit description time-and-motion study LDH content with sterile tube collecting cell supernatant.
After administration, 24 hours supernatant discarded, add 2%Trion-100X, and mix cell suspension after leaving standstill 12 hours in 4 DEG C, centrifugal 20 minutes (2000r/min), carefully collects supernatant, by test kit description time-and-motion study SOD content.
4. result of the test
All data represent with X ± SD, and one factor analysis of variance and LSD many groups mean compare the significance of group difference between two, and P<0.05 is significant difference.
4.1 impacts of PC12 cell survival rate on damage
The each embodiment of table 1 is to the result (n=10) of PC12 cell survival rate
| Group | OD value | Cell survival rate % |
| Model group | 0.6512±0.0813 | 78.37±6.33 |
| Embodiment 1 compositions | 0.803±0.0822 | 90.15±8.026 ** |
| Embodiment 2 compositions | 1.202±0.0679 | 147.30±20.38 ** |
| Embodiment 3 compositions | 1.100±0.0653 | 138.90±28.051** |
| Embodiment 4 compositions | 1.108±0.0572 | 141.50±23.20 ** |
Note: compared with model group, * * P<0.01; Compared with model group, * P<0.05
Table 1 result shows, and embodiment 1-4 compositions has good repair function to neural cell injury.
The each embodiment of table 2 is to the result (n=10) of PC12 cell SOD and LDH
| Group | SOD concentration (U/L) | LDH concentration (IU/L) |
| Blank group | 10.310±2.2360 | 1.684±0.1254 |
| Model group | 5.920±1.2340 | 2.284±0.1504 |
| Embodiment 1 compositions | 45.420±5.6771** | 1.595±0.1570 ** |
| Embodiment 2 compositions | 26.297±4.5470** | 1.829±0.1561 ** |
| Embodiment 3 compositions | 25.208±2.8990** | 1.635±0.1530** |
| Embodiment 4 compositions | 24.871±5.3820** | 1.803±0.1472 ** |
Note: compared with model group, * * P<0.01; Compared with model group, * P<0.05;
Table 2 result shows, and compared with model group, embodiment 1-4 compositions makes cell SOD vigor significantly increase, and LDH concentration significantly reduces.
Experimental example 2: clinical observation is tested
1 data and method
1.1 physical data: neuropathic pain patients 304 example, according to medical history, symptom, make diagnosis in conjunction with clinical examination analysis.Trigeminal neuralgia 45 example, sciatica 55 example, scorching 58 examples of radicular pain 65 example, postherpetic neuralgia 81 example, diabetic nerve tip.
1.2 therapeutic schemes: oral present composition every day 2 times, take l5 days 1 course for the treatment of continuously, period in a medicine is stopped using the medicine of other sacred disease.Often take medicine 1 course for the treatment of, do clinical analysis and clinical symptoms is added up.
1.3 Pain Grading standards: main suit's Pain Grading method (VRS) that Pain Grading is formulated according to WHO.0 grade: painless; I level (mild pain): though there is pain, can stand, and sleep is interference-free; H level (severe pain): sharp ache is impatient at, and needs analgesic, and sleep is disturbed, with autonomic nervous dysfunction performance or positive position.
1.4 curative effect determinate standards: after 4 courses for the treatment of of medication, judge effect.Cure: subjective symptoms disappears completely, follows up a case by regular visits to and does not recur for 2 years; Effective: cardinal symptom is improved or substantially disappeared; Effective: cardinal symptom disappears substantially; Invalid: cardinal symptom is all without improvement.
1.5 observation indexs: safety is observed: general health check-up project, the inspection of blood, urine, feces routine
Look into, the heart, Liver and kidney function inspection; Health giving quality is observed: the observation of Tibetan medicine's syndrome manifestations, neural
The observation of systemic symptom sign, blood examination.
2 results
2.1 comparitive study: 304 routine patients cure 167 examples, effective and effective 119 examples, invalid 18 examples.Total effective rate is 94.1%
Table 3 present composition treatment neuropathic pain result
| Sick kind (example) | Cure (%) | Effective and effective (%) | Invalid (%) | Total effective rate (%) |
| Trigeminal neuralgia (45) | 22（48.9） | 21（46.7） | 2（4.4） | 95.6 |
| Sciatica (55) | 32（58.2） | 20（36.4） | 3（5.5） | 94.5 |
| Radicular pain (65) | 35（53.8） | 30（46.2） | 4（6.2） | 93.8 |
| Postherpetic neuralgia (81) | 53（65.4） | 24（29.6） | 4（4.9） | 95.1 |
| Diabetic peripheral neuritis (58) | 25（43.1） | 28（48.3） | 5（8.6） | 91.4 |
Untoward reaction situation: 304 routine patients, all do not find any toxic and side effects and untoward reaction in clinical observation process.
Claims (7)
1. treat a pharmaceutical composition for neuropathic pain, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Morin 20-30 weight portion polygalic acid A15-25 weight portion syringopicroside 10-20 weight portion clerodendrin A5-15 weight portion.
2. according to claim 1: a kind of pharmaceutical composition for the treatment of neuropathic pain, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Morin 20 weight portion polygalic acid A25 weight portion syringopicroside 10 weight portion clerodendrin A15 weight portion.
3. according to claim 1: a kind of pharmaceutical composition for the treatment of neuropathic pain, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Morin 30 weight portion polygalic acid A15 weight portion syringopicroside 20 weight portion clerodendrin A5 weight portion.
4. according to claim 1: a kind of pharmaceutical composition for the treatment of neuropathic pain, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Morin 25 weight portion polygalic acid A20 weight portion syringopicroside 17 weight portion clerodendrin A10 weight portion.
5. according to claim 1: a kind of pharmaceutical composition for the treatment of neuropathic pain, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Morin 28 weight portion polygalic acid A22 weight portion syringopicroside 16 weight portion clerodendrin A8 weight portion.
6. a kind of pharmaceutical composition for the treatment of neuropathic pain according to claim 1, can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
7. a kind of pharmaceutical composition for the treatment of neuropathic pain as claimed in claim 1, is characterized in that being used for the treatment of trigeminal neuralgia, sciatica, radicular pain, postherpetic neuralgia, diabetic nerve tip is scorching.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628700.5A CN104473960A (en) | 2014-11-11 | 2014-11-11 | Pharmaceutical composition used for treating neuropathic pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628700.5A CN104473960A (en) | 2014-11-11 | 2014-11-11 | Pharmaceutical composition used for treating neuropathic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104473960A true CN104473960A (en) | 2015-04-01 |
Family
ID=52748664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410628700.5A Pending CN104473960A (en) | 2014-11-11 | 2014-11-11 | Pharmaceutical composition used for treating neuropathic pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104473960A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| CN101080224A (en) * | 2004-11-16 | 2007-11-28 | 利默里克神经科学股份有限公司 | Methods and compositions for treating pain |
| CN102429897A (en) * | 2011-09-16 | 2012-05-02 | 四川大学 | Pharmaceutical composition for improving oral bioavailability of morin |
-
2014
- 2014-11-11 CN CN201410628700.5A patent/CN104473960A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| CN101080224A (en) * | 2004-11-16 | 2007-11-28 | 利默里克神经科学股份有限公司 | Methods and compositions for treating pain |
| CN102429897A (en) * | 2011-09-16 | 2012-05-02 | 四川大学 | Pharmaceutical composition for improving oral bioavailability of morin |
Non-Patent Citations (1)
| Title |
|---|
| JUNG JIN OH 等: "Inhibitory Effect of the root of Polygala tenuifolia on Bradykinin and COX 2-Mediated Pain and Inflammatory Activity", 《TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716214A (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN108078975A (en) | Application of the pharmaceutical composition containing eucalyptol, limonene and australene in the drug for preparing treatment upper respiratory tract bacterium infection | |
| US8586053B2 (en) | Composition and use of phyto-percolate for treatment of disease | |
| CN104523722A (en) | Medicine composition for treating neuropathic pains | |
| CN102920726B (en) | Medicinal composition for preventing and treating neuropathic pain | |
| CN102861045B (en) | Medicinal composition for treating neuropathic pain | |
| CN104473960A (en) | Pharmaceutical composition used for treating neuropathic pain | |
| CN104473953A (en) | Pharmaceutical composition used for treating neuropathic pain | |
| CN104473951A (en) | Pharmaceutical composition used for treating neuropathic pain | |
| CN104523725A (en) | Pharmaceutical composition for treating neuropathic pain | |
| CN101559046A (en) | Therapeutic action of micromolecule sugar alcohol composite on nasal disease | |
| CN104069063A (en) | Hydroxyfasudil pharmaceutical composition and preparation method thereof | |
| Sharma et al. | Evaluation of mannitol as an osmotherapeutic agent in traumatic brain injuries by measuring serum osmolality | |
| CN102389449B (en) | Erigeron breviscapus extract and preparation method and application thereof | |
| CN102697757A (en) | Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy | |
| You-Qin et al. | Inhibitory effect of total flavonoids of Malus hupehensis on hepatic fibrosis induced by Schistosoma japonicum in mice | |
| Saad et al. | Continuous versus intermittent use of meropenem in septic critically ill patients: a randomized controlled trail | |
| CN102671199B (en) | Dissolving agent capable of dissolving diclazuril and ethopabate simultaneously and anticoccidial medicinal composition | |
| CN101919812B (en) | Novel formulation of piperazine ferulate and preparation method thereof | |
| CN108096273A (en) | The application of Glucose sulfate aldehydic acid oligosaccharides | |
| CN102028681A (en) | Application of peperphentonamine or salt thereof in preparing drug for preventing/treating encephalopathy | |
| Liu et al. | Study on graded therapy of hemophilic arthritis by integrative traditional Chinese and Western medicine | |
| Chunduri et al. | Comparative study of Phytal originated B17s and medicinal importance | |
| CN108938672B (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for rehabilitation treatment of ischemic cerebral apoplexy | |
| CN105194504B (en) | The more capsule that relaxes is preparing the application having in neuroprotective medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150401 |
|
| RJ01 | Rejection of invention patent application after publication |